Patients treated with quarterly or monthly fremanezumab did not experience a wearing-off effect towards the end of the dosing interval.
Why this matters
Fremanezumab, a fully humanized monoclonal antibody, is used as preventive treatment for migraines in adults and is approved for monthly and quarterly subcutaneous dosing.
As a wearing-off effect has been reported for other migraine treatments and considering the long dosing interval of fremanezumab it was important to investigate if reduced efficacy in the final weeks before the next scheduled dose also occurs with this drug.
This post hoc analysis of data from a Phase III study of fremanezumab provides evidence that patients with migraine treated with this drug do not experience a wearing-off effect.